This publish was written and revealed as a collaboration between the in-house editorial workforce at Benzinga and Tonix Prescription drugs Holding Corp. with monetary assist from Tonix. The 2 organizations work to make sure that any and all data contained inside is true and correct as of the date hereof to the perfect of their data and analysis. This content material is for informational functions solely and never supposed to be investing recommendation.
Ache administration is getting an improve, and Wall Avenue appears to be taking discover. For many years the ache drug market has been dominated by opioids that trigger hostile unwanted side effects like habit and overdose. Within the wake of the opioid disaster and the brand new limitations on prescribing them, scientists and corporations are chasing novel approaches to acute and continual ache. A brand new crop of medication is coming to the market to handle acute and doubtlessly continual ache with out most of the unwanted side effects, and that has Wall Avenue and ache victims paying shut consideration.
Vertex Units The Stage
One solely has to take a look at Vertex Prescription drugs VRTX, the drug firm pursuing acute ache with a first-in-class NaV1.8 ache sign inhibitor drug. In January, Vertex received FDA approval for VX-548 – Journavx® (suzetrigine) – its non-opioid drug for acute ache Suzetrigine. The corporate now sports activities a market capitalization of over $123 billion, based mostly additionally on its different merchandise. The trials that received approval for Journavx have been in post-surgical settings after bunionectomy or tummy-tuck. These are indications wherein quick programs of opiates are usually prescribed and are acknowledged as helpful.
One other firm going after the ache market – albeit in a unique space – with a non-opiate ache treatment for fibromyalgia is Tonix Prescription drugs Holding Corp. TNXP. Fibromyalgia is a continual ache situation, not an acute ache situation. Fibromyalgia arises due to irregular ache signaling within the mind, not like acute ache, which is brought on by tissue and nerve harm. The totally built-in biopharmaceutical company is growing its first-in-class tertiary amine tricyclic drug that acts within the central nervous system. Their drug TNX-102 SL* (cyclobenzaprine HCl sublingual tablets) is a non-opioid investigational drug concentrating on fibromyalgia, which impacts hundreds of thousands of Individuals, largely girls.
Any such ache impacts a big portion of the physique or may be particular to extremities just like the ft or arms. Fibromyalgia inflicts ache over many elements of the physique, which known as “widespread” or “multi-site” ache. Along with residing with the continual widespread ache of fibromyalgia, sufferers typically complain of fatigue and sleep issues. Two different sorts of medication are already authorised to deal with fibromyalgia, gabapentinoids like Pfizer’s PFE Lyrica® and SNRIs like Eli Lilly’s LLY Cymbalta®. Regardless of the supply of those once-popular manufacturers, many fibromyalgia sufferers are dissatisfied. In contrast to acute ache, most specialists agree that opioids ought to by no means be used to deal with fibromyalgia. Most specialists agree that opioids present no significant profit to fibromyalgia sufferers and solely result in habit.
Tonix Positioning To Lead
Like Vertex within the acute ache market, Tonix is tough at work positioning itself to change into a frontrunner in treating the continual ache of fibromyalgia with a non-addictive therapy that is within the remaining phases of in search of FDA approval.
It is sensible Tonix goes after the fibromyalgia market. As a result of fibromyalgia sufferers are usually affected for years or a long time, and TNX-102 SL is predicted for use each day at bedtime, the variety of prescriptions for every affected person is predicted to be bigger than for acute ache, which is often a two-week course. Nonetheless, each markets are massive. In response to one estimate, the continual ache drug market, which incorporates fibromyalgia, is forecast to develop from $72.10 billion in 2024 to over $115.51 billion by 2031, and the acute ache drug market is forecast to achieve $103.6 billion by 2035.
Sleep disturbance can have a big impact on chronic pain, making it really feel worse. Lack of sleep may also hyperexcite the central nervous system (CNS), decreasing ache tolerance. TNX-102 SL is a sublingual formulation that’s designed to be taken each day at bedtime and to focus on the disturbed sleep of fibromyalgia. TNX-102 SL just isn’t believed to be a sedative or hypnotic like Ambien® or Lunesta®. These conventional sedatives can fail to completely handle the sleep drawback of fibromyalgia.
FDA Approval May Come As Quickly As August
TNX 102-SL is at the moment being evaluated by the FDA and the corporate expects the FDA may situation a choice on advertising and marketing authorization on August 15, 2025. Meaning it may doubtlessly be in the marketplace in 2025, giving fibromyalgia victims a much-needed new choice. Because it stands, Tonix says 85% of fibromyalgia sufferers fail their first-line remedy, and 79% are on a number of therapies to no avail.
Fibromyalgia can happen by itself, however it might additionally happen within the context of different circumstances. The Nationwide Academies of Science, Engineering and Medication (NASEM) acknowledged in June of final yr that fibromyalgia is a diagnosable situation in Lengthy COVID. The Nationwide Institute of Well being only recently recognized that concentrating on sleep high quality is a promising method to treating lengthy COVID. Tonix has accomplished a pilot examine in multi-site ache related to Lengthy COVID and obtained encouraging outcomes, significantly on bettering fatigue.
The advice by the NASEM to diagnose fibromyalgia in acceptable lengthy COVID sufferers could increase Tonix’s addressable market. In any case, the variety of lengthy COVID victims, which based on the World Well being Group is about 6 in every 100 people who contract COVID, outnumbers those that are believed to undergo from fibromyalgia with out lengthy COVID. New knowledge from the Medical Expenditure Panel Survey assist prior findings that round 7% of adults in the U.S. have lengthy COVID, which quantities to 17.8 million adults. It is unknown what number of of those folks even have fibromyalgia.
From fibromyalgia to lengthy COVID sufferers and Wall Avenue, many are wanting with hope at a brand new class of medication to handle an unmet want: ache treatment that isn’t addictive and nonetheless efficient. Corporations like Vertex on the acute ache aspect and Tonix concentrating on fibromyalgia on the continual ache aspect, are aiming to be leaders in these burgeoning markets. With Tonix’s therapy beneath FDA assessment, it may very well be solely a matter of time earlier than that may doubtlessly change into a actuality.
*TNX-102 SL is an investigational new medication and has not been authorised for any indication.
Click here for extra data on Tonix Prescription drugs.
Picture by Keenan Constance on Unsplash.
This publish comprises sponsored content material. This content material is for informational functions solely and never supposed to be investing recommendation.
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
